Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Gastrointestinal 1CNS 1

Conditions

Neoplasms 1Leukemia, Myeloid, Acute 1Glioma 1Cholangiocarcinoma 1

Interventions

Specimen Handling 456Magnetic Resonance Spectroscopy 347pembrolizumab 287Biopsy 245Carboplatin 228Cisplatin 194Cyclophosphamide 178Paclitaxel 160Nivolumab 153Gemcitabine 147Bevacizumab 126Radiotherapy 124Dexamethasone 110Pemetrexed 101fludarabine 96Fluorouracil 95atezolizumab 93Radiation 92Docetaxel 90venetoclax 89Doxorubicin 88durvalumab 85Oxaliplatin 85Rituximab 84Leucovorin 81Capecitabine 76Prednisone 73Lenalidomide 70X-Rays 69Etoposide 67

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytochrome P-450 CYP2C9 × 30 days × Clear all
NCT07486713 2026-06-05

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

Rigel Pharmaceuticals

Phase 4 Recruiting
16 enrolled
CNSGastrointestinalOther hematologic neoplasm

Glioma, Neoplasms, Leukemia, Myeloid, Acute, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡